ArticleMolecular cancer therapeutics2020

Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.

Ulrike Weyer-Czernilofsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.